Elizabeth L. Barry, Ph.D.
Assistant Professor of Epidemiology
Assistant Professor of Community and Family Medicine
Community and Family Medicine
Dartmouth College CECS, MS 2003
University of Wisconsin-Madison, PhD 1989
Grinnell College, BA 1983
46 Centerra Parkway
Lebanon NH 03766
Office: Room 331
Dr. Barry's current research focuses on the chemoprevention of cancer and the pharmacogenetics of chemopreventative agents. She is especially interested in the role and mechanism of action of anti-inflammatory drugs (such as aspirin) and nutritional supplements (such as calcium, vitamin D and folate) as chemopreventative agents for cancer. Using data from clinical trials, Dr. Barry is currently investigating how genetic polymorphisms may modify the effectiveness of some of these drugs in the prevention of colorectal adenomas. In addition to her interest in cancer, Dr. Barry has a long-standing interest in calcium and vitamin D regulation and their role in bone health and disease (osteoporosis).
Medical Pharmacology (Calcium and Bone Pharmacology)
Barry EL, Mott LA, Sandler RS, Ahnen DJ, Baron JA. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention. Cancer Prev Res (Phila). 2011 Dec;4(12):2072-82. Epub 2011 Sep 19. (view details on MedLine)
Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2726-33. Epub 2009 Sep 15. (view details on MedLine)